Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1026706 in Healthy Male Volunteers in a Partially Randomised, Single-blind, Placebo-controlled Trial, and Investigation of Relative Bioavailability of BI 1026706 (Open-label, Randomised, Four-way Cross-over)
Latest Information Update: 29 Mar 2019
At a glance
- Drugs BI 1026706 (Primary)
- Indications Chronic obstructive pulmonary disease; Diabetic macular oedema
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 16 Jun 2014 New trial record